SPARC helps normalize the ovarian cancer malignant ascites microenvironment by downregulating the VEGF–integrin–MMP axis, reducing the levels and activation of bioactive lipids, and ameliorating downstream inflammatory (Said et al., 2007b). This evidence concerns the gene SPARC and ovarian carcinoma.